GCSAML (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K8-ac
MGNYLLRkLSCLGEN
0 1
GCSAML (human) MGNYLLRkLSCLGEN K8-ac
K17-ac
SCLGENQkkPKKGNP
0 1
GCSAML (human) SCLGENQkkPKKGNP K17-ac
K18-ac
CLGENQkkPKKGNPD
0 1
GCSAML (human) CLGENQkkPKKGNPD K18-ac
T34-p
ERKRQEMttFERKLQ
0 2
GCSAML (human) ERKRQEMttFERKLQ T34-p
T35-p
RKRQEMttFERKLQD
0 1
GCSAML (human) RKRQEMttFERKLQD T35-p
S47-p
LQDQDKKsQEVSSTs
0 1
GCSAML (human) LQDQDKKsQEVSSTs S47-p
S54-p
sQEVSSTsNQENENG
0 1
GCSAML (human) sQEVSSTsNQENENG S54-p
Y69-p
SGSEEVCyTVINHIP
0 9
GCSAML (human) SGSEEVCyTVINHIP Y69-p
S81-p
HIPHQRSsLssNDDG
0 1
GCSAML (human) HIPHQRSsLssNDDG S81-p
S83-p
PHQRSsLssNDDGyE
0 2
GCSAML (human) PHQRSsLssNDDGyE S83-p
S84-p
HQRSsLssNDDGyEN
0 2
GCSAML (human) HQRSsLssNDDGyEN S84-p
Y89-p
LssNDDGyENIDsLt
Upstream
0 24
Treatment
  • erlotinib
  • gefitinib
GCSAML (human) LssNDDGyENIDsLt Y89-p
S94-p
DGyENIDsLtRKVRQ
Upstream
0 3
Treatment
  • anti-CD3
GCSAML (human) DGyENIDsLtRKVRQ S94-p
T96-p
yENIDsLtRKVRQFR
0 1
GCSAML (human) yENIDsLtRKVRQFR T96-p
S106-p
VRQFRERsEtEyALL
0 1
GCSAML (human) VRQFRERsEtEyALL S106-p
T108-p
QFRERsEtEyALLRT
0 1
GCSAML (human) QFRERsEtEyALLRT T108-p
Y110-p
RERsEtEyALLRTSV
0 32
GCSAML (human) RERsEtEyALLRTSV Y110-p
T124-p
VSRPCSCtHEHDyEV
0 1
GCSAML (human) VSRPCSCtHEHDyEV T124-p
Y129-p
SCtHEHDyEVVFPH_
0 26
GCSAML (human) SCtHEHDyEVVFPH_ Y129-p